Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System
30.1.2026 08:30:00 CET | Business Wire | Press Release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine.
In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market.
Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinical research. With over 3,000 peer- reviewed and published articles, the company currently has 32 ongoing global clinical study projects enrolling 600+ patients with over 2,000 study visits, treating a wide range of skin types and conditions.
The launch of the Glacē system, together with the upcoming launch of the Matrix and VBeam Pro systems, provides best-in-class treatment solutions for skin health including skin tightening, texture, acne, scars, advanced vascular treatments and overall skin quality.
The Glacē System is a professional facial system designed for high-frequency skin care for medical, wellness and aesthetic providers. Engineered as a comprehensive skin purifying platform, the Glacē system functions both as a standalone facial treatment and as a clinically proven adjunct to energy-based device treatments to support improved skin quality, patient comfort and consistent results. The Glacē system enables a broader segment of practices — spanning the range from beauty-focused to medical aesthetic practices, to offer a modern, repeatable skin health treatment while enhancing combination treatment outcomes for practices using Candela devices.
The Matrix System (currently pending EU MDR clearance) is Candela’s next-generation skin renewal workstation that combines intelligent, outcomes-driven energy delivery with safety-by-design engineering. The multiapplication radiofrequency (RF) platform integrates skin resurfacing, microneedling and noninvasive wrinkle treatment within a single device to address multiple layers of the skin with precision. Powered by Candela’s signature Aesthetic Intelligence technology, the Matrix system is designed to sense, adapt and display tissue impedance in real time, supporting safe, smooth and consistent heating across applications, skin types and depths. This intelligent performance allows providers to deliver reproducible outcomes across all skin types and a wide range of indications, notably skin tightening, acne scarring, textural irregularities and collagen loss.
The Vbeam Pro system, launched in 2025 in the U.S., is the only vascular laser FDA-cleared for use in pediatric patients. It combines an advanced 595 nm pulsed dye laser with a 1064 nm Nd:YAG wavelength to offer unmatched precision, accuracy and treatment versatility. The platform is designed to effectively treat a broad spectrum of skin conditions, including pediatric and adult vascular abnormalities, rosacea, port-wine stains, acne, leg veins, spider veins, scars, benign pigmented lesions, wrinkles, warts, stretch marks, and photoaging.
“Developing innovative products that powerfully enhance skin health and youthfulness is our passion. We are excited to be unveiling the Matrix, Glacē and VBeam Pro systems here,” said Geoffrey Crouse, Chief Executive Officer of Candela. “By launching these major platforms, we are accelerating our ability to serve customers in the fast-evolving European and global market, where patient demand continues to grow, and our scientific and clinically proven treatment solutions continue to uniquely address skin quality, laxity, texture, tone and more.”
As part of this next chapter of innovation, Candela is also unveiling experience-driven customer engagement — pairing scientific exchange with immersive brand experience designed to foster engagement with key opinion leaders, partners and customers, including exclusive clinical and customer experiences held in conjunction with IMCAS.
“As someone whose practices use both the Glacē and Matrix systems, I see these platforms as highly complementary,” said Firas Al-Niaimi, MD, Professor of Laser Dermatology and a Board-Certified Dermatologist with a private practice in London. “Together, they allow us to comprehensively address skin health — including skin laxity, texture and tone — safely with precision and confidence. Candela continues to invest not only in technology, but also in addressing the needs of a broader cross-section of aesthetic practices and their patients in clinically validated ways that meaningfully and positively impact our patient experience.”
Candela will showcase the Glacē, Matrix and VbeamPro Systemsat IMCAS 2026, featuring live product demonstrations, scientific presentations, a dedicated symposium on Epigenetics and Skin Health, and other engagement opportunities with its global clinical community.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260129455611/en/
Contacts
Sarvar Kothavala
VP, Global Advocacy, Professional Education & Strategic Insights
Mobile: +1.415.760.0902
Email: sarvark@candelamedical.com
Elena Yacoub
We. Communications
Office: +1.425.578.1757
Email: eyacoub@wecommunications.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press Release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press Release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity30.1.2026 07:00:00 CET | Press Release
Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learned about the effects of menopause on the skin by going through it themselves, with most finding out about it in their 40s.2 However, over 30% would have liked to learn about this in their 30s and over 50% are at best neutral or dissatisfied with their knowledge on the topic.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129610958/en/ To address this knowledge gap, Galderma will leverage its expertise in dermatology to advance awareness, understanding, education, and treatment approaches for menopause-related skin changes. With around 85% of aesthetic patients being female, it is important to
Convera Appoints Industry Leader Meaghan Riley as Chief Commercial Officer to Scale Commercial Growth and Expand Revenue Opportunities29.1.2026 17:14:00 CET | Press Release
Convera, a global leader in commercial payments, today announces the appointment of Meaghan Riley to Chief Commercial Officer, as the company continues its growth trajectory, expands to new markets, and drives scalable revenue opportunities across geographies and sectors. Prior to Convera, Meaghan was Chief Operating Officer for Google Cloud North America, where she led a major go-to-market transformation and launched high-growth segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129799440/en/ Meaghan Riley, Chief Commercial Officer, Convera “Meaghan’s impressive career journey and proven track record brings exceptional experience and unique assets that will strengthen our leadership team at this pivotal moment in Convera’s journey,” said Patrick Gauthier, CEO, Convera. “Meaghan’s leadership will be instrumental in delivering on our commitment to make global business payments simpler and smarter—serving our customer
New Year, New Solutions: AMRA Medical Continues Commitment to Innovation & Data-Driven Excellence29.1.2026 16:23:00 CET | Press Release
AMRA Medical, the global leader in MRI-based fat distribution and muscle composition analytics, is excited to share our brand repositioning supported by the launch of a refreshed website and the introduction of a new tagline, “Insights Within.” This strategic update reflects AMRA’s commitment to placing clients and collaborators at the center of our vision: to be the most trusted, insights-driven imaging partner in the pursuit of preventing and curing disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129457626/en/ The new website provides a more structured and transparent presentation of AMRA’s biomarkers and research services, enabling our partners to have a clear understanding of our offerings, as well as the scientific value and applications of these solutions. For the first time, we’re introducing Imaging Biomarkers and Insights Biomarkers: clearly-defined, intentional offerings that are designed with your trial
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom